Cargando…

Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials

BACKGROUND: Slower than planned recruitment is a major factor contributing to the delay or failure of randomised controlled trials to report on time. There is a limited evidence base regarding the optimisation of recruitment strategies. Here we performed an observational review of our experience in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, Thomas, Alexander, Sarah, Blackstone, James, De Angelis, Floriana, John, Nevin, Doshi, Anisha, Beveridge, Judy, Braisher, Marie, Gray, Emma, Chataway, Jeremy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361231/ https://www.ncbi.nlm.nih.gov/pubmed/35945550 http://dx.doi.org/10.1186/s13063-022-06588-z

Ejemplares similares

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
por: Chataway, Jeremy, et al.
Publicado: (2020)

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
por: Connick, Peter, et al.
Publicado: (2018)

Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
por: Williams, Thomas, et al.
Publicado: (2022)

Enhancing involvement of people with multiple sclerosis in clinical trial design
por: Gray, Emma, et al.
Publicado: (2023)

Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis: From the MS-STAT Randomized Controlled Trial
por: Williams, Thomas E., et al.
Publicado: (2022)

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial
por: Chan, Dennis, et al.
Publicado: (2017)

Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique
por: Tur, Carmen, et al.
Publicado: (2021)

Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis
por: Li, Vivien, et al.
Publicado: (2022)

Strengthening Mental Abilities with Relational Training (SMART) in multiple sclerosis (MS): study protocol for a feasibility randomised controlled trial
por: Golijani-Moghaddam, Nima, et al.
Publicado: (2022)

Optimising recruitment into trials using an internal pilot
por: Bertram, W., et al.
Publicado: (2019)

Data on the optimisation of GC-MS/MS method for the simultaneous determination of compounds from food contact material
por: Žnideršič, Luka, et al.
Publicado: (2019)

In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
por: Sips, Fianne L. P., et al.
Publicado: (2022)

Optimisation of Solid-Phase Extraction and LC-MS/MS Analysis of Six Breast Cancer Drugs in Patient Plasma Samples
por: Turković, Lu, et al.
Publicado: (2023)

MS Energize: Field trial of an app for self-management of fatigue for people with multiple sclerosis
por: Babbage, Duncan R., et al.
Publicado: (2019)

"Hit smart and early" - MS-Therapie mit Ozanimod
por: Ottenjann, Henrike
Publicado: (2023)

Smouldering multiple sclerosis: the ‘real MS’
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Proteins recruited by SH3 domains of Ruk/CIN85 adaptor identified by LC-MS/MS
por: Havrylov, Serhiy, et al.
Publicado: (2009)

Clinical trials site recruitment optimisation: Guidance from Clinical Trials: Impact and Quality
por: Zahren, Christine, et al.
Publicado: (2021)

HPLC-MS/MS Oxylipin Analysis of Plasma from Amyotrophic Lateral Sclerosis Patients
por: Mastrogiovanni, Mauricio, et al.
Publicado: (2022)

Uveitis prior to clinical presentation of Multiple Sclerosis (MS) is associated with better MS prognosis
por: Raskin, Eyal, et al.
Publicado: (2022)

Development of an ID-LC–MS/MS method using targeted proteomics for quantifying cardiac troponin I in human serum
por: Asicioglu, Meltem, et al.
Publicado: (2023)

The effect of optimised patient information materials on recruitment in a lung cancer screening trial: an embedded randomised recruitment trial
por: Parker, Adwoa, et al.
Publicado: (2018)

Validation by collaborative trial of a method for the determination by GC–MS and LC–MS/MS of boar taint marker compounds in pork tissue
por: Buttinger, Gerhard, et al.
Publicado: (2020)

Development and Optimisation of HILIC-LC-MS Method for Determination of Carbohydrates in Fermentation Samples
por: Pismennõi, Dmitri, et al.
Publicado: (2021)

Optimising a urinary extraction method for non-targeted GC–MS metabolomics
por: Olivier, Cara, et al.
Publicado: (2023)

AZD-1222/elasomeran/tozinameran: Multiple sclerosis (MS) and relapse of MS: 16 case reports
Publicado: (2022)

OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis
por: Dobson, Ruth, et al.
Publicado: (2021)

Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI)
por: Donovan, Jenny L., et al.
Publicado: (2016)

Usability and acceptability of a cognitive training intervention (SMART) for people with multiple sclerosis (MS): A prefeasibility formative evaluation
por: Frost, Alexandra C., et al.
Publicado: (2022)

xtalPiMS: A PiMS-based web application for the management and monitoring of crystallization trials
por: Daniel, Ed, et al.
Publicado: (2011)

A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS
por: Hardmeier, Martin, et al.
Publicado: (2017)

Assessing heterogeneity of treatment effect in multiple sclerosis trials
por: Sormani, Maria Pia, et al.
Publicado: (2023)

A Predictive Model for Corticosteroid Response in Individual Patients with MS Relapses
por: Rakusa, Martin, et al.
Publicado: (2015)

Innovative methods for optimising clinical trial recruitment and retention within primary care
por: Lawton, Sarah, et al.
Publicado: (2015)

Equipoise across the patient population: optimising recruitment to a randomised controlled trial
por: Whybrow, Paul, et al.
Publicado: (2017)

Characteristics, comorbidities, and complications in multiple sclerosis (MS) and non-MS patients undergoing lumbar fusion for deformity
por: Sulovari, Aron, et al.
Publicado: (2023)

Embedding qualitative research in randomised controlled trials to improve recruitment: findings from two recruitment optimisation studies of orthopaedic surgical trials
por: Scantlebury, Arabella, et al.
Publicado: (2021)

Comparison of Flow Injection-MS/MS and LC-MS/MS for the Determination of Ochratoxin A
por: Zhang, Kai
Publicado: (2021)

Study of the Stability, Uptake and Transformations of Zero Valent Iron Nanoparticles in a Model Plant by Means of an Optimised Single Particle ICP-MS/MS Method
por: Wojcieszek, Justyna, et al.
Publicado: (2023)

Determination of Nine Fentanyl Drugs in Hair Samples by GC-MS/MS and LC-MS/MS
por: Wei, Qi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6mejpvp3ev8okc9csf9b6ugm23